Unique ID issued by UMIN | UMIN000045069 |
---|---|
Receipt number | R000051469 |
Scientific Title | Influence of nucleotide on muscle atrophy |
Date of disclosure of the study information | 2021/08/10 |
Last modified on | 2025/02/06 12:01:56 |
Influence of nucleotide on muscle atrophy
Influence of nucleotide on muscle atrophy
Influence of nucleotide on muscle atrophy
Influence of nucleotide on muscle atrophy
Japan |
Healthy subject
Not applicable | Adult |
Others
NO
To assess the influence of nucleotide on muscle atrophy
Efficacy
Exploratory
Pragmatic
Not applicable
muscle atrophy
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
Institution is not considered as adjustment factor.
2
Educational,Counseling,Training
Food |
Nucleotide, 14 days
Placebo (cellulose), 14 days
20 | years-old | <= |
25 | years-old | >= |
Male
(1) BMI of less than 30 kg/m2
(2) Must be in good physical condition and able to perform the test safely
(3) Those who voluntarily participate in the test with written consent
(1) Those who have metal or other objects in their body that prevent them from performing MRI measurements.
(2) Those who routinely perform upper limb training.
(3) Patients with glucose metabolism disorder, endocrine disorder, kidney, liver, or digestive organ disease.
(4) Patients undergoing medical treatment by a physician.
(5) Those who have been diagnosed as suffering from heart disease.
(6) Patients with type I or type II diabetes
(7) Those who have been diagnosed as requiring treatment or re-examination at a medical check-up within the past year
(8) Those who participated in another clinical trial within the last 3 months
(9) Those who have used illicit drugs in the last 6 months.
(10) Patients who have had alcoholism or drug addiction in the last 6 months
24
1st name | Atsushi |
Middle name | |
Last name | Kubota |
Juntendo University
Graduate School of Health and Sports Science
2701695
1-1, Hiragagakuendai, Inzai, Chiba
+81476981001
akubota@juntendo.ac.jp
1st name | Atsushi |
Middle name | |
Last name | Kubota |
Juntendo University
Graduate School of Health and Sports Science
2701695
1-1, Hiragagakuendai, Inzai, Chiba
+81476981001
akubota@juntendo.ac.jp
Juntendo University
YAMASA CORPORATION
Profit organization
Japan
Ethics committee of Juntendo University Graduate School of Sports and Health Science
1-1, Hiragagakuenndai, Inzai, Chiba
+81476981001
sc-kyomu@juntendo.ac.jp
NO
順天堂大学(千葉県)
2021 | Year | 08 | Month | 10 | Day |
https://x.gd/bINX9
Published
https://x.gd/bINX9
22
Results: Both groups showed a significant decrease in muscle thickness at MT70. The relative decrease was greater in the placebo group (2.4 +- 2.8%) than in the UMP group (0.0 +- 2.0%), significantly (p = 0.034) at 1 week. However, no significant difference was observed at MT50 and MT60.
2025 | Year | 02 | Month | 06 | Day |
A total of 22 healthy men were enrolled in this study. The inclusion criteria were defined as follows: (1) age exceeding 20 and below 25 years, (2) BMI not more than 30 kg/m2, (3) satisfactory physical condition with the ability to safely perform the experiment, and (4) provision of written consent and voluntary participation in the experiment. Conversely, exclusion criteria comprised (1) regular upper extremity training; (2) presence of glucose metabolism disorders, endocrine disorders, kidney/liver disease, and digestive disease; (3) current medical medication prescribed by a doctor; (4) diagnosed heart disease; (5) type I or type II diabetes; (6) a physical examination within the past year requiring treatment or reexamination; (7) participation in another clinical experiment within the past 3 months; (8) use of illicit drugs within the past 6 months; or (9) a history of alcoholism or drug addiction within the past 6 months. The study's purpose and methods were communicated verbally and in writing to the participants, who then provided written consent.
One participant opted not to continue for personal reasons before controlled trial. The remaining 21 participants were randomly assigned to two groups: (1) receiving 5'-UMP, 2Na (UMP group, n = 11) and (2) a placebo group (n = 10), and they were allowed to consume the assigned test supplement during the 2-week detraining phase. Measurements were taken weekly during the detraining period, and data from the 21 participants who completed the study were used for analysis.
No adverse events were observed.
Muscle thickness
Completed
2021 | Year | 06 | Month | 30 | Day |
2021 | Year | 06 | Month | 30 | Day |
2021 | Year | 08 | Month | 23 | Day |
2022 | Year | 08 | Month | 31 | Day |
2021 | Year | 08 | Month | 05 | Day |
2025 | Year | 02 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051469